XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.23.1

License Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended |  |
--- | --- | --- | --- | ---
Jan. 31, 2023 | Mar. 31, 2022 | Oct. 31, 2021 | Mar. 31, 2021 | Apr. 30, 2020 | Mar. 31, 2023 | Dec. 31, 2022 | Oct. 06, 2022
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  | 36,974,396 | 35,110,016 |
Pfizer License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Payment for license fee |  |  |  | $ 25,000,000.0 |  |  |  |
Milestone and royalties required |  | $ 0 |  |  |  | $ 0 |  |
Upfront payments | $ 8,000,000.0 |  |  | $ 5,000,000.0 |  | $ 8,000,000.0 |  |
Common stock, shares issued |  |  |  |  |  | 1,811,594 |  | 2,229,654
Pfizer License Agreement | IPO |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Number of common shares issued upon conversion of preferred stock |  |  | 1,911,015 |  |  |  |  |
Pfizer License Agreement | Series B Convertible Preferred Stock |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Issuance of convertible preferred stock shares |  |  | 12,152,145 |  |  |  |  |
Issuance of convertible preferred stock value |  |  | $ 20,000,000.0 |  |  |  |  |
LegoChem License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Milestone and royalties required |  | 0 |  |  |  | $ 0 |  |
Amount payable related to licensed products |  |  |  |  |  | 0 |  |
Estimated cost to purchase licensed products |  |  |  |  |  | 7,000,000.0 |  |
Biosion License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Milestone and royalties required |  | 0 |  |  |  | 0 |  |
Biosion License Agreement | Research and Development Expenses |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Upfront fee |  | 10,000,000.0 |  |  |  |  |  |
University License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Common stock issued to university |  |  |  |  | 48,919 |  |  |
Milestone and royalties required |  | $ 0 |  |  |  | $ 0 |  |

X
- Definition Common stock issued to university. + References No definition available. + Details
Name: | pyxs_CommonStockIssuedToUniversity
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Convertible preferred stock shares issued value. + References No definition available. + Details
Name: | pyxs_ConvertiblePreferredStockSharesIssuedValue
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Estimated cost to purchase licensed products. + References No definition available. + Details
Name: | pyxs_EstimatedCostToPurchaseLicensedProducts
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Issuance of convertible preferred stock shares. + References No definition available. + Details
Name: | pyxs_IssuanceOfConvertiblePreferredStockShares
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone and royalties incurred. + References No definition available. + Details
Name: | pyxs_MilestoneAndRoyaltiesIncurred
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of common shares issued upon conversion of preferred stock. + References No definition available. + Details
Name: | pyxs_NumberOfCommonSharesIssuedUponConversionOfPreferredStock
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for license fee. + References No definition available. + Details
Name: | pyxs_PaymentForLicenseFee
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront fee. + References No definition available. + Details
Name: | pyxs_UpfrontFee
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payments. + References No definition available. + Details
Name: | pyxs_UpfrontPayments
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date of obligations due all related parties. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(C)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(3),(4)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueToRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |